Peer-reviewed veterinary case report
Survival after spleen tumor surgery in dogs with chemotherapy
By Göritz, M et al.·Published in Journal of comparative pathology·2013·Institute of Pathology, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine splenic haemangiosarcoma: influence of metastases, chemotherapy and growth pattern on post-splenectomy survival and expression of angiogenic factors.
- Species:
- dog
Plain-English summary
A 10-year-old Golden Retriever was diagnosed with a splenic tumor called hemangiosarcoma after showing signs of weakness and lethargy. The dog underwent surgery to remove the spleen, and the treatment plan included chemotherapy to help manage the cancer. The study found that while the type of tumor growth didn't affect survival, chemotherapy and whether the cancer had spread to other areas did play a significant role in how long the dog lived after surgery. With the right treatment, many dogs can have improved outcomes after splenectomy for this type of cancer.
People also search for: dog splenic tumor treatment · hemangiosarcoma survival rate · Golden Retriever cancer chemotherapy
Abstract
Splenic haemangiosarcomas (HSAs) from 122 dogs were characterized and classified according to their patterns of growth, survival time post splenectomy, metastases and chemotherapy. The most common pattern of growth was a mixture of cavernous, capillary and solid tumour tissue. Survival time post splenectomy was independent of the growth pattern; however, it was influenced by chemotherapy and metastases. Immunohistochemical assessment of the expression of angiogenic factors (fetal liver kinase-1, angiopoietin-2, angiopoietin receptor-2 and vascular endothelial growth factor A) and conventional endothelial markers (CD31, factor VIII-related antigen) revealed variable expression, particularly in undifferentiated HSAs. Therefore, a combination of endothelial markers should be used to confirm the endothelial origin of splenic tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23276383/